title: Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab.
authors.forename: Gurjit
authors.initials: G
authors.lastname: Chohan
authors.forename: Yael
authors.initials: Y
authors.lastname: Barnett
authors.forename: John
authors.initials: J
authors.lastname: Gibson
authors.forename: Stephen W R
authors.initials: SW
authors.lastname: Reddel
authors.forename: Michael H
authors.initials: MH
authors.lastname: Barnett
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance / Q000187:drug effects*; D004401:Dysarthria / Q000150:complications / Q000188:drug therapy; D006646:Histiocytosis, Langerhans-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging / Q000523:psychology; D008297:Male; D008875:Middle Aged
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab